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PPolymorphism in KIF6 Gene and Benefit
From Statins After Acute Coronary Syndromes
Results From the PROVE IT-TIMI 22 Study
Olga A. Iakoubova, MD, PHD,* Marc S. Sabatine, MD, MPH, FACC,† Charles M. Rowland, MS,*
Carmen H. Tong, BS,* Joseph J. Catanese, BS,* Koustubh Ranade, PHD,‡ Katy L. Simonsen, PHD,‡
Todd G. Kirchgessner, PHD,‡ Christopher P. Cannon, MD, FACC,† James J. Devlin, PHD,*
Eugene Braunwald, MD, MACC†
Alameda, California; Boston, Massachusetts; and Princeton, New Jersey
Objectives We explored whether the benefit of intensive versus moderate statin therapy would be greater in carriers of KIF6
719Arg than in noncarriers.
Background The 719Arg variant of Trp719Arg (rs20455), a polymorphism in kinesin-like protein 6, is associated with greater
risk of coronary events and greater benefit from pravastatin versus placebo.
Methods We genotyped 1,778 acute coronary syndrome patients within the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin
Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22) trial and investigated different inten-
sities of statin therapy in carriers of 719Arg and in noncarriers using Cox proportional hazards models that ad-
justed for traditional risk factors.
Results Benefit from intensive, compared with moderate, statin therapy was significantly greater in the 59% of the
cohort who were carriers (hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.45 to 0.77) than in those who
were noncarriers (HR 0.94, 95% CI 0.70 to 1.27; p  0.018 for interaction between 719Arg carrier status and
treatment). Absolute risk reduction was 10.0% in carriers versus 0.8% in noncarriers. The benefit of intensive
therapy in carriers was significant as early as day 30 of therapy. Carriers and noncarriers did not differ in on-
treatment low-density lipoprotein cholesterol, triglyceride, or C-reactive protein (CRP) levels.
Conclusions Carriers of 719Arg receive significantly greater benefit from intensive statin therapy than do noncarriers, a supe-
rior benefit that appears to be due to a mechanism distinct from lipid or CRP lowering. Functional studies of the
KIF6 kinesin are warranted, given the consistent association of Trp719Arg with risk of coronary events and sta-
tin benefit. (J Am Coll Cardiol 2008;51:449–55) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.017t
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lifferential risk of disease and differential response to
reatment due to the genetic diversity of patient populations
as been reported for a number of diseases and treatments
1–3). If the genetic variants responsible for these differ-
See page 456
nces were known, such variants could facilitate personal-
zed medicine by identifying those at elevated risk of disease,
rom *Celera, Alameda, California; †TIMI Study Group, Cardiovascular Division,
righam & Women’s Hospital, Harvard Medical School, Boston, Massachusetts; and
he ‡Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New
ersey. Supported by research grants from Bristol-Myers Squibb Pharmaceutical
esearch Institute (to Drs. Braunwald and Cannon). Genotyping and statistical
nalysis was funded by Celera.a
Manuscript received August 13, 2007; revised manuscript received September 28,
007, accepted October 22, 2007.hose likely to benefit from a particular therapy, or those less
ikely to benefit (4,5).
To that end, we have previously reported that the
rp719Arg polymorphism in kinesin-like protein 6 (encoded
y KIF6) is associated with a greater risk of coronary events in
he placebo arms of the CARE (Cholesterol and Recurrent
vents) and WOSCOPS (West of Scotland Coronary Pre-
ention Study) trials. The KIF6 kinesin is a member of a family
f molecular motors involved in intracellular transport of
rotein complexes, membrane organelles, and messenger ribo-
ucleic acid along microtubules (6,7). Carriers of the 719Arg
llele of the KIF6 kinesin had a 50% increased risk of events
ompared with noncarriers (8). The 719Arg allele has also
een associated with risk of coronary heart disease (CHD) in
he ARIC (Atherosclerosis Risk in Communities) study, a
arge prospective, population-based study of over 15,000 middle-
ged Americans with long-term follow-up (9), and in the WHS
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KIF6 Trp719Arg in the PROVE IT-TIMI 22 Trial January 29, 2008:449–55(Women’s Health Study), a large
prospective, population-based study
of over 25,000 apparently healthy
women (10).
In addition to a greater risk of
coronary events, carriers of the KIF6
719Arg allele received greater ben-
efit from pravastatin, compared
with placebo, than did noncarriers
in the CARE and WOSCOPS
trials (8). Recent reviews of statin
pharmacogenomics have high-
lighted the importance of investi-
ating genetic variants associated with statin response in
ultiple prospective studies (11–13). Given the importance of
ultiple studies and the use of intensive lipid lowering in
ontemporary clinical practice, we thought that it would be
mportant to determine whether the presence of the 719Arg
llele also affects the magnitude of clinical benefit from other,
ore intensive, statin regimens. We therefore examined
hether the clinical benefit from intensive lipid-lowering
herapy with high-dose atorvastatin (80 mg/day), compared
ith standard-dose pravastatin (40 mg/day), would be greater
mong carriers of the KIF6 719Arg allele than among non-
arriers in the PROVE IT-TIMI 22 (Pravastatin or Atorva-
tatin Evaluation and Infection Therapy: Thrombolysis in
yocardial Infarction 22) trial (14). In this trial, intensive
herapy with high-dose atorvastatin (80 mg/day) resulted in
reater protection against death or cardiovascular events than
id moderate therapy with standard-dose pravastatin (40
g/day, the same dose used in the CARE and WOSCOPS
rials) in patients with a recent acute coronary syndrome.
ethods
tudy population. The study population for this genetic
tudy was derived from the PROVE IT-TIMI 22 trial,
hich has been described previously (14). Briefly, the trial
omprised 4,162 patients who had been hospitalized for
n acute coronary syndrome within 10 days preceding
nrollment and who were enrolled while in stable condi-
ion and after any planned revascularization. Patients
ere enrolled at 349 centers in 8 countries between
ovember 2000 and December 2001 and randomized to
igh-dose atorvastatin (80 mg/day) or standard-dose
ravastatin (40 mg/day) and to gatifloxacin or placebo
sing a double-blind, 2  2 factorial design. The 2,061
atients who provided institutional review board–
pproved informed consent for genetic analysis were
ligible for inclusion in this genetic study (all of these
atients were enrolled in North America). We excluded
2 of these patients because of inadequate quantity or
uality of deoxyribonucleic acid and 39 owing to missing
alues for one or more of the traditional risk factors that
ere required for multivariate analysis. Because only
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CRP  C-reactive protein
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
LDL-C  low-density
lipoprotein cholesterol0.3% of the patients were nonwhite, which did not Arovide sufficient power for a separate analysis of ethnic
roups, we included only the white patients in this
enetic analysis. After these exclusions, 1,778 patients
emained in the genetic cohort of the PROVE IT-TIMI
2 trial.
nd point and laboratory values. The end point for this
enetic study was the same as the primary end point of the
riginal PROVE IT-TIMI 22 study (i.e., death from any
ause or major cardiovascular events), which included myo-
ardial infarction, documented unstable angina requiring
ospitalization, revascularization with either percutaneous
oronary intervention or coronary artery bypass grafting (if
hese procedures were performed at least 30 days after
andomization), and stroke. All laboratory measurements
ere made in a core facility (14). Low-density lipoprotein
holesterol (LDL-C) and triglyceride levels were measured at
aseline and at the following scheduled visits: 30 days, 4
onths, 8 months, 16 months, and the end of follow-up;
ollow-up lasted 18 to 36 months (mean 24 months).
-reactive protein (CRP) levels were measured at baseline and
t the following scheduled visits: 30 days, 4 months, and the
nd of follow-up. KIF6 Trp719Arg genotypes were deter-
ined using an allele-specific real-time polymerase chain
eaction genotyping assay at a core facility (15). The
rp719Arg genotypes determined with this assay have been
hown to be 99.8% concordant with genotypes determined
sing a different genotyping technology (16). The primer
equences are available upon request.
tatistical analyses. All reported p values are 2-sided.
ifferences between baseline characteristics were assessed
y the Wilcoxon rank-sum test (continuous variables) or by
isher exact test (discrete variables). We assessed deviation
rom Hardy-Weinberg equilibrium using an exact test (17).
chi-square test was used to test for differences in genotype
requencies across studies. Cox proportional hazards models
ere used to assess the effect of intensive therapy, compared
ith moderate therapy, on incident events in KIF6 719Arg
arriers and noncarriers. To estimate hazard ratios (HRs)
djusted for the effects of other risk factors and study design
ariables, baseline covariates were included in the Cox
odels and were coded either continuously (age, LDL-C,
igh-density lipoprotein cholesterol [HDL-C], triglyceride,
nd CRP levels) or dichotomously (gender, smoking [cur-
ent vs. never or past], hypertension [defined as history of
ypertension, systolic blood pressure 140 mm Hg, or
iastolic blood pressure 90 mm Hg], diabetes, and treat-
ent with gatifloxacin). After estimating the benefit of 80
g atorvastatin, compared with 40 mg pravastatin, sepa-
ately in carriers and noncarriers, the p value for interaction
etween KIF6 719Arg carrier status and statin treatment
as determined from likelihood ratio tests that evaluated
otential heterogeneity of the HRs. The Kaplan-Meier
ethod was used to estimate the cumulative incidence of
eath or major cardiovascular events, and differences were
ssessed with the log-rank test at 2 years of follow-up.
bsolute risk reduction was estimated from the differences
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January 29, 2008:449–55 KIF6 Trp719Arg in the PROVE IT-TIMI 22 Trialn the cumulative incidence of events at 2 years of follow-up.
AS version 9 software (SAS Institute, Cary, North Caro-
ina) was used for all regression models and for generating
aplan-Meier estimates.
esults
aseline characteristics and allele frequencies. The base-
ine characteristics for traditional risk factors of this genetic
ohort of the PROVE IT-TIMI 22 trial according to KIF6
19Arg carrier status are presented in Table 1. The preva-
ence of risk factors for CHD was similar in carriers and
oncarriers of the 719Arg variant, with the exception that
urrent smoking was less frequent among 719Arg carriers
p  0.042). The treatment groups in this genetic cohort
lso were well balanced with regard to baseline traditional
isk factors (p  0.29; data not presented). Carriers of the
19Arg variant constituted 58.9% of the PROVE IT-TIMI
2 trial genetic cohort. The genotype frequencies were
3.5%, 45.4%, and 41.1% for Arg/Arg, Arg/Trp, and
rp/Trp, respectively, and the distribution of these geno-
ypes did not deviate from Hardy-Weinberg expectations
p  0.51). These genotype frequencies were not signifi-
antly different (p  0.32) than the frequencies reported for
he CARE trial cohort and the control group in a nested
ase-control study of the WOSCOPS trial (8).
aseline Characteristics of the Patients According to KIF6 Trp719
Table 1 Baseline Characteristics of the Patients According to
Characteristic
ArgArg Genotype
(n  240)
Arg/Trp Genotype
(n  808)
Age, yrs 58.1  10.9 57.3  11.0
Male, n (%) 188 (78.3) 636 (79.0)
BMI, kg/m2 30.4  6.2 30.1  5.7
Smoking status, n (%)
Current 87 (36.3) 291 (36.0)
Past 251 (34.4) 307 (38.0)
Never 173 (23.7) 210 (26.0)
Diabetes, n (%) 41 (17.1) 150 (18.6)
Hypertension, n (%)* 138 (57.5) 452 (55.9)
Prior statin therapy, n (%) 60 (25.0) 209 (25.9)
Total cholesterol, mg/dl
Median 187 181
IQR 163–208 162–207
Low-density lipoprotein
cholesterol, mg/dl
Median 108 106
IQR 89–129 89–130
High-density lipoprotein
cholesterol, mg/dl
Median 39 38
IQR 33–46 33–45
Triglycerides, mg/dl
Median 160 163
IQR 121–228 127–218
Hypertension was defined as the history of hypertension, systolic blood pressure140mmHg, or d
enotypes were tested with the Kruskal-Wallis test for continuous variables and the chi-square test f
ested with the Wilcoxon rank sum test for continuous variables and Fisher exact test for discrete variabl
BMI  body mass index; IQR  interquartile range.utcome of therapy and KIF6 Trp719Arg. Carriers and
oncarriers of KIF6 719Arg received significantly different
enefit from high-dose atorvastatin therapy compared with
tandard-dose pravastatin therapy. Specifically, in carriers of
he 719Arg allele, high-dose atorvastatin therapy, compared
ith standard-dose pravastatin therapy, reduced the risk of
eath or major cardiovascular events by 41% (adjusted HR
.59, 95% confidence interval [CI] 0.45 to 0.77; p  0.001)
Table 2). The HRs were similar in Arg/Arg homozygotes
nd in Arg/Trp heterozygotes, which is consistent with a
ominant genetic model. In contrast, high-dose atorvastatin,
ompared with standard-dose pravastatin, was of no signif-
cant benefit in noncarriers (adjusted HR 0.94, 95% CI 0.70
o 1.27; p  0.70) (Table 2). This difference in benefit
etween carriers and noncarriers was significant (p  0.018
or interaction between KIF6 719Arg carrier status and
reatment) (Table 2).
In terms of absolute event rates, among carriers of the
IF6 719Arg variant the Kaplan-Meier estimates of the
umulative incidence of death or major cardiovascular events
t 2 years was 26.0% in the standard-dose pravastatin group
nd 16.1% in the high-dose atorvastatin group (log-rank
 0.001) (Fig. 1A), an absolute risk reduction of 10.0%
95% CI 4.9% to 15.0%) favoring the intensive-therapy
egimen. However, among noncarriers, the cumulative in-
enotypes and 719Arg Carrier Status
Trp719Arg Genotypes and 719Arg Carrier Status
ariant Noncarriers,
p/Trp Genotype
(n  730)
Arg Variant Carriers,
Arg/Arg  Arg/Trp
Genotypes
(n  1,048) p Value† p Value‡
57.7  11.0 57.5  11.0 0.53 0.54
564 (77.3) 826 (78.8) 0.72 0.45
30.1  5.8 30.1  5.9 0.92 0.92
0.09 0.042
306 (41.9) 378 (36.1)
251 (34.4) 389 (37.1)
173 (23.7) 281 (26.8)
113 (15.5) 191 (18.2) 0.28 0.14
418 (57.3) 590 (56.3) 0.84 0.70
183 (25.1) 269 (25.7) 0.93 0.78
0.65 0.80
184 183
161–208 162–207
0.79 0.67
108 107
89–129 89–130
0.82 0.74
38 38
33–45 33–45
0.85 0.85
164 162
125–219 126–219
blood pressure90mmHg. †Associations between baseline characteristics and KIF6 Trp719Arg
ete variables. ‡Associations between baseline characteristics and KIF6 719Arg carrier status wereArg G
KIF6
Arg V
Tr
iastolic
or discres.
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KIF6 Trp719Arg in the PROVE IT-TIMI 22 Trial January 29, 2008:449–55idence of death or major cardiovascular events was essen-
ially the same in the 2 treatment groups: 24.7% in the
tandard-dose pravastatin group and 23.9% in the high-dose
torvastatin group (log-rank p  1.0) (Fig. 1B), an absolute
isk reduction of 0.8% (95% CI 5.6% to 7.3%).
Moreover, in carriers of 719Arg, the substantial and
ignificant benefit from intensive therapy, compared with
oderate therapy, was evident as early as 30 days after
andomization and remained significant throughout the
rial: the unadjusted HR at 30 days was 0.18 (95% CI 0.04
o 0.81) (Fig. 2). In contrast to the early benefit seen in
arriers, in noncarriers there was no significant benefit of
ntensive therapy, compared with moderate therapy, at any
ime point (Fig. 2).
Because LDL-C cholesterol, CRP, and triglyceride levels
re risk factors for cardiovascular events and can be reduced
y intensive statin therapy (18,19), we explored whether the
hanges in the levels of these risk factors in response to
reatment with either high-dose atorvastatin or standard-
ose pravastatin differed between carriers and noncarriers of
he KIF6 719Arg allele. We found no evidence in either the
igh-dose atorvastatin group or in the standard-dose prav-
statin group that these risk factors differed between carriers
nd noncarriers at any time during therapy. Specifically, in
oth treatment groups, no significant differences in median
DL-C, CRP, or triglyceride levels were found between
arriers and noncarriers at baseline or at any scheduled visit
uring the study (p  0.3; data not presented).
IF6 719Arg and risk of events. Because a previous
enetic study of the CARE and WOSCOPS trials had
hown that carriers of the KIF6 719Arg variant were at
ncreased risk of CHD compared with noncarriers in
lacebo-treated patients and that standard-dose pravastatin
reatment ameliorated the increased risk associated with the
19Arg variant (8,9), we investigated the association be-
ween 719Arg allele and risk in the PROVE IT-TIMI 22
rial. As observed in the CARE and WOSCOPS trials, we
ound that in the standard-dose pravastatin–treated patients
ffect of 80 mg Atorvastatin Versus 40 mg Pravastatin on Deathr Maj r Cardiovascul r Events According to KIF6 Trp719Arg Geno
Table 2 Effect of 80 mg Atorvastatin Versus 40 mg Pravastatinor Major Cardiovascular Events According to KIF6 Trp7
Subgroup Treatment On-Trial CHD, n Total, n
Arg/Arg  Arg/Trp Atorvastatin 88 525
Pravastatin 139 523
Trp/Trp Atorvastatin 86 367
Pravastatin 88 363
Arg/Trp Atorvastatin 66 391
Pravastatin 113 417
Arg/Arg Atorvastatin 22 134
Pravastatin 26 106
Adjusted for gender, age, smoking, hypertension, diabetes, low-density lipoprotein cholesterol, h
etween KIF6 carrier status and treatment.
CHD  coronary heart disease; CI  confidence interval; HR  hazard ratio; ref  reference grarriers of the KIF6 719Arg allele were not at increased (isk of death or major coronary events compared with
oncarriers (adjusted HR 1.12, 95% CI 0.85 to 1.45; p 
.45). In the high-dose atorvastatin group, carriers were
ctually at decreased risk (adjusted HR 0.65, 95% CI 0.48
o 0.88; p  0.005).
iscussion
n this genetic study of the PROVE IT-TIMI 22 study, a
linical trial that enrolled patients with a recent acute
oronary syndrome, we found that intensive statin therapy
80 mg atorvastatin per day, the highest approved dose of
his potent statin), compared with standard statin therapy
40 mg pravastatin per day), was significantly more effica-
ious in reducing death and major cardiovascular events in
he 59% of the patients who were carriers of the KIF6
19Arg variant than in the remaining 41% of the population
ho were noncarriers (relative risk reduction 41% vs. 6%,
espectively). In the face of equal lipid lowering in carriers
nd in noncarriers, absolute risk reductions were 10.0% in
arriers and 0.8% in noncarriers after 2 years of treatment.
hus, only 10 carriers of the KIF6 719Arg variant needed
o be treated with intensive statin therapy to prevent 1
vent; in contrast, the number needed to treat for
oncarriers was 125.
Our findings in the PROVE IT-TIMI 22 trial are
onsistent with and extend observations made in 2 other
istinct clinical trial populations: CARE and WOSCOPS
8). The KIF6 719Arg variant has now been investigated in
enetic studies of 3 trials that included over 6,200 patients:
studies of 40 mg pravastatin (a lipophilic statin) per day
ersus placebo (8) and the present study of 80 mg atorva-
tatin (a hydrophilic statin) per day versus 40 mg pravastatin
er day. In all 3 of these genetic studies, the efficacy of the
ore intensive lipid-lowering therapy in reducing coronary
vents was greater in carriers (37% to 50% relative risk
eductions) than in noncarriers (6% to 20% risk reductions)
Death
rg Genotype
Unadjusted Adjusted*
95% CI p Value HR 95% CI p Value
9 0.45–0.78 0.001 0.59 0.45–0.77 0.001
0 ref 1.00 ref
8 0.72–1.31 0.87 0.94 0.70–1.27 0.70
0 ref 1.00 ref
interaction p  0.014† interaction p  0.018†
8 0.43–0.79 0.001 0.57 0.42–0.78 0.001
0 ref 1.00 ref
5 0.37–1.14 0.13 0.69 0.38–1.24 0.21
0 ref 1.00 ref
sity lipoprotein cholesterol, and treatment with gatifloxacin. †Likelihood ratio test of interactiontype
on
19A
HR
0.5
1.0
0.9
1.0
0.5
1.0
0.6
1.0
igh-denFig. 3).
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January 29, 2008:449–55 KIF6 Trp719Arg in the PROVE IT-TIMI 22 TrialAmong carriers of KIF6 719Arg the superiority of inten-
ive, compared with standard, statin therapy was substantial
nd significant as early as 30 days after the start of the
reatment; however, in noncarriers there was no significant
enefit from intensive therapy at any point during the study.
his early superiority of intensive therapy in carriers may be
ue to an early plaque-stabilizing effect of the intensive-
reatment regimen, a pleiotropic effect that has been pro-
osed to explain the early benefit from statin therapy that
ppears not to be due to LDL lowering (20,21). A pleio-
ropic mechanism would be consistent with our observation
hat on-treatment median LDL-C levels did not differ
etween carriers and noncarriers. Additionally, this early
enefit from intensive statin therapy in carriers of KIF6
19Arg variant is likely to be distinct from anti-
Figure 1 Primary End Point According
to Treatment and KIF6 719Arg Carrier Status
Kaplan-Meier estimates of the cumulative incidence of death or major cardio-
vascular events in the high-dose atorvastatin and standard-dose pravastatin
treatment groups: (A) among carriers of the KIF6 719Arg variant; (B) among
noncarriers of the KIF6 719Arg variant. The log-rank p values are based on 2
years of follow-up. The unadjusted hazard ratios (HR) and 95% confidence inter-
vals (CI) are based on 30 months of follow-up.nflammatory mechanisms related to the reduction of CRP Ievels, because carriers and noncarriers did not differ in
edian CRP levels at baseline or during the trial.
The KIF6 719Arg variant was associated with an in-
reased risk of coronary events in the ARIC study, a large
opulation-based cohort of over 15,000 subjects (9), in the
HS, a large population-based cohort of over 25,000
omen (10), and in the placebo groups of the WOSCOPS
nd CARE trials (8). However, statin therapy appears to
meliorate this risk: carriers of the 719Arg variant who were
reated with standard-dose pravastatin were not at increased
isk compared with noncarriers in the CARE and
OSCOPS trials (8). And similarly, in the PROVE
T-TIMI 22 trial, carriers of 719Arg who were treated with
tandard-dose pravastatin were not at increased risk com-
ared with noncarriers who were treated with standard-dose
ravastatin. A hypothesis that could explain these observa-
ions is that, for patients on statin therapy, the risk of
oronary events depends on the balance between the 2
ffects associated with the 719Arg variant: increased risk of
oronary events and enhanced benefit from statin therapy.
hus, among patients on placebo, carriers of 719Arg were at
0% greater risk compared with noncarriers. However,
mong patients on standard-dose pravastatin, carriers and
oncarriers were at similar levels of risk, because the
ncreased risk associated with the 719Arg allele was bal-
nced, or offset, by the increased benefit from statin therapy
ssociated with the 719Arg allele. Finally, among patients
n the more potent high-dose atorvastatin regimen, carriers,
ith their enhanced benefit from statin therapy, were
ctually at decreased risk of coronary events compared with
oncarriers.
In the KIF6 719Arg variant, a basic arginine residue
eplaces a nonpolar tryptophan residue. Because this amino
cid substitution is in a predicted coiled-coil region of the
IF6 protein, the change might affect the cargo binding of
he kinesin (22). Several kinesins have been implicated in
he pathogenesis of chronic diseases, including neurodegen-
rative diseases, type 2 diabetes, and Alzheimer’s disease
23). We believe that functional studies that explore the
echanism by which the KIF6 kinesin and the 719Arg
ariant affect cardiovascular disease are now warranted,
iven the consistency of the association in multiple prospec-
ive cohorts. Such studies are particularly important to help
xplain why the benefit from atorvastatin (80 mg), com-
ared with pravastatin (40 mg) differed between carriers and
oncarriers despite similar on-therapy plasma LDL-C and
RP levels.
tudy limitations. This genetic study was not a part of the
tudy protocol for the original PROVE IT-TIMI 22 trial
nd included only the white patients who were predomi-
antly middle-aged men; therefore, the effect of the inten-
ive statin therapy in carriers and noncarriers of the KIF6
19Arg variant should be further investigated in additional
thnic groups, women, and older patients after acute coro-
ary syndromes. Although genetic studies of the PROVE
T-TIMI 22, WOSCOPS, and CARE trials (comprising
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KIF6 Trp719Arg in the PROVE IT-TIMI 22 Trial January 29, 2008:449–55bout 6,000 patients) showed that carriers of the KIF6
19Arg allele receive significant clinical benefit from ator-
astatin (80 mg) compared with pravastatin (40 mg), and
rom pravastatin (40 mg) compared with placebo (8),
Figure 2 Time to Benefit According to KIF6 719Arg Carrier Sta
Hazard ratio for death or major cardiovascular events at 30, 90, and 180 days, 2
standard-dose pravastatin therapy according to KIF6 719Arg carrier status. The cu
Kaplan-Meier method. CI  confidence interval.
Figure 3 Effect of Statin Therapy
According to KIF6 Trp719Arg in 3 Studies
Effect of statin therapy on fatal coronary heart disease or nonfatal myocardial
infarction in the CARE trial, coronary heart disease in the WOSCOPS trial, and
death or major cardiovascular events in the PROVE IT-TIMI 22 trial according to
KIF6 719Arg carrier status. In both the CARE trial, a secondary prevention
study, and the WOSCOPS trial, a primary prevention study, the effect of prava-
statin (40 mg) was compared with placebo. In the PROVE IT-TIMI 22 trial, a
secondary prevention study, the effect of atorvastatin (80 mg) was compared
with pravastatin (40 mg). We used Cox proportional hazards models in the
CARE and PROVE IT-TIMI 22 trials and conditional logistic regression in the
nested case-control study of the WOSCOPS trial. CI  confidence interval.ohereas noncarriers do not, these observations should be
onfirmed in other larger studies. In addition, although 2
ifferent statins were studied, our findings may not extend
o other statins. It is also not clear whether differential
enefit between carriers and noncarriers from intensive
tatin therapy compared with standard treatment is re-
tricted only to benefit from high-dose atorvastatin com-
ared with standard-dose pravastatin or can be extrapolated
o different doses of the same statin. This question could be
ddressed by conducting a genetic study of KIF6
rp719Arg polymorphism in clinical trials that compare
ifferent doses of the same statin.
onclusions
arriers of the 719Arg allele are at increased risk of fatal or
onfatal coronary events when not treated with statins
8–10), and they clearly benefit from statin therapy, whether
t be standard-dose pravastatin compared with placebo (8)
r high-dose atorvastatin therapy compared with standard-
ose pravastatin. In contrast, noncarriers not only were at
ower risk than carriers in the ARIC and WHS trials and in
he placebo groups of the CARE and WOSCOPS trials,
ut noncarriers also received less benefit from statin treat-
ent than did carriers in the CARE, WOSCOPS, and
ROVE IT-TIMI 22 trials. The absence of significant
enefit from intensive statin therapy in noncarriers does not
reclude the possibility that a portion of noncarriers do
enefit from statin therapy, but it does suggest that noncar-
iers may be treated with standard statin therapy and also
ith other lipid-modifying drugs or by strategies that target
and at the end of follow-up. High-dose atorvastatin therapy was compared with
ve incidence of death or major cardiovascular events was estimated by thetus
years,
mulatither risk factors such as hypertension, diabetes, or smok-
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January 29, 2008:449–55 KIF6 Trp719Arg in the PROVE IT-TIMI 22 Trialng. The biological explanations for the observed difference
n treatment benefit should be provided by functional
tudies of this kinesin motor protein, studies which could
lso offer important additional insights into the biology of
ipid metabolism and acute coronary syndromes that could,
n turn, generate novel targets for therapeutic intervention
nd lead to better-tailored therapy for patients.
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